Why a new book on angiogenesis and why now? For the first time concepts proposed over 30 years ago have found clinical validation. In the last two years the first antiangiogenic agents have been approved by the FDA for the treatment of cancer and age-related macular degeneration. Not surprisingly, this clinical success has raised a new set of basic and clinical questions that need to be addressed.
Angiogenesis: From Basic Science to Clinical Applications presents the latest advances in basic science and reviews the status of the clinical applications of angiogenic growth factors and inhibitors. It explores current molecular and genetic findings on the regulation of angiogenesis, discusses the results of clinical trials and identifies the pathological conditions that are most likely to benefit from such treatments.
Edited by a leading researcher in the field, the book includes contributions from multiple experts in their respective disciplines, supplemented by illustrations and photographs. A unique combination of information on basic science and clinical trials research, this book is truly a state-of-the-art review of the state of the science.
Vascular Endothelial Growth Factor: Pathophysiology and Clinical Implications. Signal Transduction of VEGF Receptors toward Angiogenesis. Growth Factors and Lymphangiogenesis. Notch and Vascular Development. Neural Guidance Molecules in Vascular Development. Neuropilins, Receptors for the VEGF and Semaphorin Families, Link Angiogenesis and Axon Guidance. Non-Angiogenic Functions of VEGF. Contribution of Pro-Angiogenic Hematopoietic Cells to Vascularization of Tumor and Ischemic Tissue. Selected Antiangiogenic Drugs as Potentially Effective Universal Chemosensitizers. Using an Anti-VEGF Monoclonal Antibody to Treat Cancer. Ocular Neovascularization. Targeting VEGF for Neovascular Age-Related Macular Degeneration and Macular Edema. Therapeutic Angiogenesis for Cardiovascular Disease.